中析研究所
分析 · 研发 · 检测

中析研究所
Zhongxi Research Institute
分析 · 研发 · 检测
Peptide, Protein & Small-Molecule Analytical Centre
+86 400-640-9567 · 010@yjsyi.com
https://www.yjsba.com/jcxm/qita/16188.html
CMA Accredited · CNAS Accredited · ISO/IEC 17025

CERTIFICATE OF ANALYSIS

Issued by an ISO/IEC 17025-accredited laboratory · raw data appended (page 2)

PASS
QC released for dispatch

Scan to verify

CJC-1295 + Ipamorelin — 10mg

CJC-1295 (No DAC) 5mg + Ipamorelin 5mg

1. PRODUCT IDENTIFICATION

Composition	CJC-1295 (No DAC) 5mg + Ipamorelin 5mg	**Manufacture date**	15 May 2026
Type	Multi-component peptide blend	**Date of analysis**	23 May 2026
CAS	See component table	**Storage**	−20 °C, dark, desiccated
Label fill	10mg	**Client**	Rejenesis Enterprises LLC (Rejenesis Peptides)
Lot / Batch	ZX260512-614 / B28586		

2. ANALYTICAL TEST RESULTS

Test	Method	Specification	Result	Verdict
Appearance	Visual	White/off-white powder	White to off-white lyophilized powder	**PASS**
Identity (each component)	LC-MS	All components confirmed	Conforms	**PASS**
Component split	RP-HPLC quantitation	Each within ±10% of label	Conforms (see §3)	**PASS**
Water content	Karl Fischer	≤ 8.0%	1.1%	**PASS**
Counter-ion: acetate	Ion chromatography	Report (3.0–15.0%)	9.8%	**PASS**
Bacterial endotoxin	LAL (USP <85>)	< 5.0 EU/mg	0.15 EU/mg	**PASS**
Heavy metals	ICP-MS (ICH Q3D)	Conforms	Conforms	**PASS**

3. COMPONENT-RESOLVED RESULTS

Component	CAS	Label → found	Identity (obs.)	Purity	Verdict
CJC-1295 (No DAC)	863288-34-0	5mg → 5.1mg	avg 3368.0 Da	98.89%	**PASS**
Ipamorelin	170851-70-4	5mg → 5.1mg	[M+H]+ 712.9	98.66%	**PASS**

CONCLUSION
All tested parameters CONFORM to the acceptance specifications. The batch is of high chromatographic purity (≥ 98%) with an impurity profile, identity and residual/contaminant results meeting pharmaceutical-grade quality requirements. Material released. Supporting RP-HPLC chromatogram and ESI-MS spectrum are appended on page 2.

DLW.

Dr. Li Wenhua
Analyst · 23 May 2026 · Zhongxi Research Institute

DFH.

Dr. Fang Hong (QC Manager)
Approved by · 23 May 2026 · Zhongxi Research Institute

中析研究所
分析 · 研发 · 检测

中析研究所
Zhongxi Research Institute
分析 · 研发 · 检测
Peptide, Protein & Small-Molecule Analytical Centre
+86 400-640-9567 · 010@yjsyi.com
https://www.yjsba.com/jcxm/qita/16188.html
CMA Accredited · CNAS Accredited · ISO/IEC 17025

APPENDIX — ANALYTICAL RAW DATA

CJC-1295 + Ipamorelin 10mg · Lot ZX260512-614 · Cert. ZXR-COA-2026-26303

Scan to verify

Figure 1. RP-HPLC Chromatogram (UV 220 nm)



Peak #	RT (min)	Area (µV·s)	Area %	Assignment
1	12.24	536922	49.92	Ipamorelin
2	23.46	521287	49.92	CJC-1295 (No DAC)
3	20.66	1458	0.16	Impurity / related substance

Figure 2. ESI-MS Spectrum (positive ion mode)



Interpretation

Spectrum shows overlapping charge-state envelopes for each component, resolved by LC-MS. Deconvoluted component masses: CJC-1295 (No DAC) 3368.0 Da (Δ 3 ppm); Ipamorelin 711.9 Da (Δ 0 ppm) — each matching its reference standard. Component identities confirmed; per-component HPLC quantitation in Section 3.

Methods — RP-HPLC: Agilent 1260 Infinity II; Zorbax SB-C18 4.6×250 mm, 5 µm; A: 0.1% TFA in water, B: 0.1% TFA in MeCN; 10–70% B over 30 min; 1.0 mL/min; 25 °C; 20 µL injection. MS: AB Sciex TripleTOF, ESI+, capillary 4.5 kV, deconvolution by Bio Tool Kit. KF: Metrohm 901. IC: Thermo Dionex ICS-6000. ICP-MS: Agilent 7900.